LDN (Low-Dose Naltrexone) is an off-label, low-dose use of a medication originally approved to treat opioid and alcohol addiction. In smaller doses (0.1–6.0 mg/day), it may help reduce inflammation, modulate the immune system, and decrease pain, especially in conditions like Ehlers-Danlos Syndrome and chronic musculoskeletal pain.
Why Dr. Bluestein Prescribes It
For patients with EDS, HSD, MCAS, POTS, and ME/CFS, pain is often widespread, complex, and frustrating to manage. In her clinical experience, LDN can be a helpful part of a multimodal strategy: not a magic bullet, but a meaningful tool.
LDN Benefits
- Reduced musculoskeletal and neuropathic pain
- Improved sleep quality and less post-exertional malaise
- Greater emotional resilience and autonomic balance
- Mast cell stabilization and improved tolerance of triggers
- Modulation of the immune system in patients with chronic inflammation
Conditions Where LDN Is Commonly Used or Studied
- Neurological and pain disorders: Fibromyalgia, complex regional pain syndrome, multiple sclerosis, migraine, and others.
- Autoimmune diseases: Hashimoto's thyroiditis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and more.
- Chronic inflammatory conditions: ME/CFS, Long COVID, mast cell activation syndrome, interstitial cystitis, and pelvic pain syndromes.
- Mental health and neuropsychiatric conditions: Depression, PTSD, anxiety disorders, and autism spectrum disorders with autoimmune or GI symptoms.
- Gastrointestinal and metabolic conditions: IBS, SIBO, celiac disease, nonalcoholic fatty liver disease, and diabetes.
- Oncology: Used adjunctively in breast, colorectal, and pancreatic cancers, and glioblastoma, to improve immune surveillance and potentially reduce side effects.
How It Works
Mechanistically, LDN works by temporarily blocking opioid receptors, leading to a rebound increase in endorphins. It also inhibits Toll-Like Receptor 4 (TLR4), reducing glial activation and neuroinflammation, and modulates immune function to promote balance without causing full immunosuppression.